A Global Call to Action on familial hypercholesterolemia (FH), a critically under-recognized and inadequately handled public health issue, was released today by the FH Foundation and the World Heart Federation.
The report, which was written by a global panel of scientific authorities, leaders in advocacy, public health officials, and people with FH from 40 countries, was published in JAMA Cardiology. It highlights glaring gaps in FH screening and guideline-based treatment, which is the most common cause of early and severe heart disease.
FH is a hereditary metabolic condition that affects 34 million individuals globally and is present in all racial and ethnic groups. FH should be identified and treated within the first two decades of life since it results in elevated LDL-cholesterol levels from birth. Untreated FH patients have a 20-fold increased chance of developing cardiovascular disease and dying from it (CVD). However, if diagnosed and treated, heart attacks, strokes and the need for surgery can be prevented.
The FH Foundation and World Heart Federation organised the multinational coalition to review and revise the World Health Organization's (WHO) 1998 report on Familial Hypercholesterolemia, which included important recommendations. Nine out of ten people born with FH go undiagnosed since few of these suggestions have been consistently carried out on a country-by-country basis in the 20 years after that publication.
According to Katherine Wilemon, founder and CEO of the FH Foundation, "Familial hypercholesterolemia represents an unparalleled opportunity for prevention of heart disease around the world.Our goal in launching this Call to Action is to draw attention to the fact that we have the scientific knowledge and efficient treatments to eliminate inherited coronary heart disease but have neglected generations of families. The time has come to make familial hypercholesterolemia a top public health concern."
The FH Global Call to Action coalition points to mounting scientific evidence, the commercialization of novel therapies, and technological advancements as additional reasons for public health officials and governments to commit to early screening and coordinated lifetime care for this sizable and vulnerable population.
According to Jean-Luc Eiselé, CEO of the World Heart Federation, "the success of the specific and implementable recommendations we release today will depend on cooperation from governments, which is why we are jointly addressing them as a global community now." "Each of the participating organisations is dedicated to promoting better and wider access to FH care in their own nations. An extraordinary chance to stop cardiovascular disease in its early stages in future generations globally is provided by the Global Call to Action on FH.
Source: The FH foundation
Greenlife Pharmova is a leading company in therapeutic fields like virology, transplantation, and cancer. Greenlife Pharmova and pharmaceuticals businesses work well together, and our knowledge of the growing genetic sciences enables us to create customized therapeutic strategies and integrated healthcare solutions. The range of healthcare services and products offered by Greenlife Pharmova includes genetic risk factor screening, disease prevention, disease diagnosis and treatment, and monitoring the effectiveness of those treatments. Greenlife Pharmova makes a distinctive contribution to improved healthcare. Greenlife Pharmova aims to lessen suffering and enhance people's health and quality of life on a global scale.
Check all our latet News and Recent updates at a single glance.
